Zentalis first patient dosed in Phase 3 ASPENOVA trial for azenosertib in Cyclin E1+ PROC

Zentalis Pharmaceuticals, Inc.

Phase 3 ASPENOVA compares azenosertib 400mg QD 5:2 to standard-of-care chemo in ~420 Cyclin E1+ platinum-resistant ovarian cancer patients.
Trial designed as confirmatory study to support full approval, with DENALI Part 2 topline expected by year-end 2026 for accelerated approval path.
400mg QD 5:2 dose selected based on DENALI Part 2a interim analysis showing differentiated response rate over 300mg with comparable safety.
Collaborators include GOG Foundation, ENGOT, and APGOT; trial identifier NCT07546500.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.